Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model

Brain Research Bulletin

Volumn 78, Issue 2-3, 2009, Pages 85-90

  Warraich, S T ^a   Allbutt, H N ^a   Billing, R ^a   Radford, J ^a   Coster, M J ^b   Kassiou, M ^b,c   Henderson, J M ^a  

^a Institute for Biomedical Research   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

6 Hydroxydopamine; Apomorphine; Locomotion; NMDA receptor antagonist; Parkinsonism; Rotation

Indexed keywords

4 TRIFLUOROMETHOXY N (2 TRIFLUOROMETHYL BENZYL) BENZAMIDE; APOMORPHINE; BENZAMIDE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BENZAMIDINES; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; IMMUNOHISTOCHEMISTRY; LEVODOPA; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TYROSINE 3-MONOOXYGENASE;

EID: 58749092676     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.08.023     Document Type: Article

References (34)

1. Allbutt H.N., and Henderson J.M. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J. Neurosci. Methods 159 (2007) 195-202
2. Bracha H.S., and Shults C. Spontaneous asymmetric curling behavior in hemiparkinsonism; a human equivalent of the lesioned-circling rodent behavior. Life Sci. 40 (1987) 127-130
3. Calon F., Dridi M., Hornykiewicz O., Bedard P.J., Rajput A.H., and Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 (2004) 1075-1084
4. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18 (2003) 241-253
5. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14 (2003) 404-416
6. Carpinella I., Crenna P., Calabrese E., Rabuffetti M., Mazzoleni P., Nemni R., and Ferrarin M. Locomotor function in the early stage of Parkinson's disease. IEEE Trans. Neural Syst. Rehabil. Eng. 15 (2007) 543-551
7. Claiborne C.F., McCauley J.A., Libby B.E., Curtis N.R., Diggle H.J., Kulagowski J.J., Michelson S.R., Anderson K.D., Claremon D.A., Freidinger R.M., Bednar R.A., Mosser S.D., Gaul S.L., Connolly T.M., Condra C.L., Bednar B., Stump G.L., Lynch J.J., Macaulay A., Wafford K.A., Koblan K.S., and Liverton N.J. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 13 (2003) 697-700
8. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., and Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57 (2000) 342-352
9. Durif F., Deffond D., Dordain G., and Tournilhac M. Apomorphine and diphasic dyskinesia. Clin. Neuropharmacol. 17 (1994) 99-102
10. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., and Calabresi P. A critical interaction between NR2B and MAGUK in L-dopa induced dyskinesia. J. Neurosci. 26 (2006) 2914-2922
11. Hallett P.J., and Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 102 (2004) 155-174
12. Henderson J.M., Annett L.E., Ryan L.J., Chiang W., Hidaka S., Torres E.M., and Dunnett S.B. Subthalamic nucleus lesions induce deficits as well as benefits in the hemiparkinsonian rat. Eur. J. Neurosci. 11 (1999) 2749-2757
13. Henderson J.M., Schleimer S.B., Allbutt H.N., Dabholkar V., Abela D., Jovic J., and Quinlivan M. Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism. Behav. Brain Res. 162 (2005) 222-232
14. Henderson J.M., Watson S., Halliday G.M., Heinemann T., and Gerlach M. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav. Brain Res. 139 (2003) 105-113
15. Henderson J.M., and Watson S.H. Convulsive and postural effects of lesioning the mid-substantia nigra pars reticulata in naive and 6-hydroxydopamine lesioned rats. Brain Res. Bull. 60 (2003) 179-185
16. Honey C.R., and Shen H. Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus. Neurosci. Lett. 249 (1998) 151-154
17. Hornykiewicz O. Brain monoamines and parkinsonism. Natl. Inst. Drug Abuse Res. Monogr. Ser. 3 (1975) 13-21
18. Hudson J.L., Fong C.S., Boyson S.J., and Hoffer B.J. Conditioned apomorphine-induced turning in 6-OHDA-lesioned rats. Pharmacol. Biochem. Behav. 49 (1994) 147-154
19. Jonkers N., Sarre S., Ebinger G., and Michotte Y. MK801 supresses the L-dopa-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 926 (2002) 149-155
20. Klopman G., and Sedykh A. An MCASE approach to the search of a cure for Parkinson's Disease. BMC Pharmacol. 2 (2002) 8
21. Kolchinsky A. Neurosurgical intervention for Parkinson's disease: an update. Surg. Neurol. 56 (2001) 277-281
22. Loftis J.M., and Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97 (2003) 55-85
23. Martinez-Martin P. Clinical gait and balance scales for Parkinson's disease. J. Neurol. Sci. 221 (2004) 125 (author reply 127)
24. Micieli G., Tosi P., Marcheselli S., and Cavallini A. Autonomic dysfunction in Parkinson's disease. Neurol. Sci. 24 Suppl. 1 (2003) S32-S34
25. Montastruc J.L., Rascol O., and Senard J.M. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci. Biobehav. Rev. 21 (1997) 477-480
26. Morrisette M., Dridi M., Calon F., Tahar A.H., Meltzer L.T., Bedard P.J., and Di Paolo T. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adensoine A2A receptors. Synapse 60 (2006) 239-250
27. Nash J.E., and Brotchie J.M. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov. Disord. 17 (2002) 455-466
28. Nash J.E., Ravenscroft P., McGuire S., Crossman A.R., Menniti F.S., and Brotchie J.M. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 188 (2004) 471-479
29. Pickel V.M., Joh T.H., Field P.M., Becker C.G., and Reis D.J. Cellular localization of tyrosine hydroxylase by immunohistochemistry. J. Histochem. Cytochem. 23 (1975) 1-12
30. Pollack A.E., and Haisley E.C. NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats. Brain Res. 897 (2001) 213-216
31. Schallert T., and Hall S. 'Disengage' sensorimotor deficit following apparent recovery from unilateral dopamine depletion. Behav. Brain Res. 30 (1988) 15-24
32. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
33. Tzschentke T.M. Glutamatergic mechanisms in different disease states: overview and therapeutical implications-an introduction. Amino Acids 23 (2002) 147-152
34. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493